<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="887">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181116</url>
  </required_header>
  <id_info>
    <org_study_id>05-02-18-06</org_study_id>
    <nct_id>NCT00181116</nct_id>
  </id_info>
  <brief_title>Levetiracetam for Benign Rolandic Epilepsy</brief_title>
  <official_title>Efficacy of Levetiracetam for Language Dysfunction Associated With Benign Epilepsy With Centrotemporal Spikes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test if the language problems commonly seen in children with
      benign rolandic epilepsy would improve by switching anticonvulsants to levetiracetam.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 6 month study in which children on another anticonvulsant would have EEG, language
      testing, and a clinic visit at baseline. They would then be rapidly transitioned off of
      their current anticonvulsant and onto levetiracetam (Keppra). Repeat EEG and language
      testing would be done after 6 months to evaluate for improvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Language improvement</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure control</measure>
  </secondary_outcome>
  <enrollment>6</enrollment>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 6-12

          -  Benign rolandic epilepsy

          -  Language difficulties as reported by parents or teachers

          -  On another anticonvulsant other than levetiracetam

        Exclusion Criteria:

          -  Prior use of levetiracetam

          -  On 2 or more anticonvulsants

          -  Language problems prior to epilepsy

          -  Another seizure disorder

          -  Status epilepticus within the past 6 months

          -  Significant psychiatric disease

          -  Progressive neurologic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric H Kossoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bello-Espinosa LE, Roberts SL. Levetiracetam for benign epilepsy of childhood with centrotemporal spikes-three cases. Seizure. 2003 Apr;12(3):157-9.</citation>
    <PMID>12651081</PMID>
  </reference>
  <reference>
    <citation>Kossoff EH, Boatman D, Freeman JM. Landau-Kleffner syndrome responsive to levetiracetam. Epilepsy Behav. 2003 Oct;4(5):571-5.</citation>
    <PMID>14527502</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <lastchanged_date>March 26, 2009</lastchanged_date>
  <firstreceived_date>September 10, 2005</firstreceived_date>
  <keyword>Epilepsy</keyword>
  <keyword>Benign rolandic</keyword>
  <keyword>Levetiracetam</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
